Yu-Fei Wang

17 Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment

Abstract Background Clear cell renal cell carcinoma (ccRCC) remains difficult to cure due to tumor antigen heterogeneity, on-target off-tumor (OTOT) toxicity risks, and a profoundly immunosuppressive tumor microenvironment (TME). While the combination of anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab) demonstrated c...